New shot aims to tame blood disorders when other treatments fail

NCT ID NCT07083960

Recruiting now Disease control Sponsor: Ouro Medicines Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 33 times

Summary

This early study tests a new drug called OM336 in adults with autoimmune cytopenias—conditions where the immune system attacks blood cells. The goal is to check safety and how the body processes the drug. About 32 people whose disease has not responded to at least one prior treatment will receive multiple doses under the skin.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AIHA - COLD AUTOIMMUNE HEMOLYTIC ANEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Icon Cancer Center South Brisbane
RECRUITING

Brisbane, Queensland, 4066, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Liverpool Hospital
RECRUITING

Sydney, New South Wales, 2107, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Canberra Hospital
RECRUITING

Canberra, Australian Capital Territory, 2605, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

AIHA - COLD AUTOIMMUNE HEMOLYTIC ANEMIA AIHA - WARM AUTOIMMUNE HEMOLYTIC ANEMIA ITP - IMMUNE THROMBOCYTOPENIA ITP - IMMUNE THROMBOCYTOPENIA